Progress in Pharmacological and Clinical Research of Dapagliflozin
- VernacularTitle:达格列净的药理及临床研究概述
- Author:
Qian NI
;
Yufei FENG
;
Yifang PEI
;
Ying HAN
- Publication Type:Journal Article
- Keywords:
Dapagliflozin;
Diabetes mellitus;
Sodium-glucose cotransporter 2 inhibitor
- From:
China Pharmacist
2014;(11):1947-1949
- CountryChina
- Language:Chinese
-
Abstract:
Pharmacology, pharmacokinetics, clinical study and safety of dapagliflozin in the treatment of type 2 diabetes mellitus were reviewed in the paper. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin can reduce HbA1c, FPG and body weight of patients with type 2 diabetes mellitus. The main adverse reaction is genital infection. The antihypertensive effect of dapagliflo-zin is still under study at present.
